Cargando…

Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease

The purpose of this article is to review eliglustat tartrate, a substrate reduction therapy, for the treatment of Gaucher disease type 1 (GD1). GD is an rare inborn error of metabolism caused by accumulation of lipid substrates such as glucosylceramide within the monocyte-macrophage system that affe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bennett, Lunawati L, Turcotte, Kelsey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554398/ https://www.ncbi.nlm.nih.gov/pubmed/26345314 http://dx.doi.org/10.2147/DDDT.S77760

Ejemplares similares

Profile of eliglustat tartrate in the management of Gaucher disease
por: Sechi, Annalisa, et al.
Publicado: (2016)

Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease [Corrigendum]
Publicado: (2015)

Profile of eliglustat tartrate in the management of Gaucher disease [Corrigendum]
Publicado: (2016)

Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapy
por: Kim, Yoo-Mi, et al.
Publicado: (2017)

Budget Impact Analysis of Eliglustat for the Treatment of Gaucher Disease Type 1 in the United States
por: Nalysnyk, Luba, et al.
Publicado: (2018)

Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial
por: Pleat, Rebecca, et al.
Publicado: (2016)

The Clinical Efficacy of Imiglucerase versus Eliglustat in Patients with Gaucher's Disease Type 1: A Systematic Review
por: Nabizadeh, Azita, et al.
Publicado: (2018)

Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat
por: Kamath, Ravi S., et al.
Publicado: (2014)

Gaucher Disease Types I and III Responded Well to Substrate Reduction Therapy Using Eliglustat
por: Harai, Nozomi, et al.
Publicado: (2023)

Outcomes after 18 months of eliglustat therapy in treatment‐naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial
por: Mistry, Pramod K., et al.
Publicado: (2017)

Clinical response to eliglustat in treatment-naïve patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
por: Ibrahim, Jennifer, et al.
Publicado: (2016)

Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1
por: Peterschmitt, M. Judith, et al.
Publicado: (2019)

Real‐world effectiveness of eliglustat in treatment‐naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2020)

Effects of paroxetine, ketoconazole, and rifampin on the metabolism of eliglustat, an oral substrate reduction therapy for Gaucher disease type 1
por: Vu, Lucie, et al.
Publicado: (2020)

Safety and efficacy of eliglustat combined to enzyme replacement therapy for lymphadenopathy in patients with Gaucher disease type 3
por: Lee, Ni-Chung, et al.
Publicado: (2022)

Pregnancy outcome in women with Gaucher disease type 1 who had unplanned pregnancies during eliglustat clinical trials
por: Lukina, Elena, et al.
Publicado: (2020)

A Japanese Patient with Gaucher Disease Treated with the Oral Drug Eliglustat as Substrate Reducing Therapy
por: Komada, Naoto, et al.
Publicado: (2021)

Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial
por: Lukina, Elena, et al.
Publicado: (2018)

Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy
por: Istaiti, Majdolen, et al.
Publicado: (2022)

P1541: PRELIMINARY RESULTS OF TWO YEARS FOLLOW-UP OF TYPE 1 GAUCHER DISEASE PATIENTS TREATED WITH ELIGLUSTAT IN TRAZELGA PROJECT.
por: Serrano-Gonzalo, I., et al.
Publicado: (2022)

A Quantitative Systems Pharmacology Model of Gaucher Disease Type 1 Provides Mechanistic Insight Into the Response to Substrate Reduction Therapy With Eliglustat
por: Abrams, Ruth, et al.
Publicado: (2020)

Impact on bone microarchitecture and failure load in a patient with type I Gaucher disease who switched from Imiglucerase to Eliglustat
por: Sidhu, Karamjot, et al.
Publicado: (2020)

Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results
por: Mistry, Pramod K., et al.
Publicado: (2021)

P1588: LONG-TERM REAL-WORLD EFFECTIVENESS OF ELIGLUSTAT IN TREATMENT-NAÏVE AND SWITCH PATIENTS ENROLLED IN THE INTERNATIONAL COLLABORATIVE GAUCHER GROUP (ICGG) GAUCHER REGISTRY
por: Mistry, Pramod, et al.
Publicado: (2023)

Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease
por: Kleytman, Nathaniel, et al.
Publicado: (2021)

Suicidal attempt with eliglustat overdose
por: Nadler, Johannes, et al.
Publicado: (2022)

Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
por: Rosenbloom, Barry E., et al.
Publicado: (2022)

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism
por: Furderer, Makaila L., et al.
Publicado: (2022)

Spotlight on taliglucerase alfa in the treatment of pediatric patients with type 1 Gaucher disease
por: Gupta, Punita, et al.
Publicado: (2017)

Coagulation Parameters in Adult Patients With Type-1 Gaucher Disease
por: Serratrice, Christine, et al.
Publicado: (2019)

The role of brimonidine tartrate gel in the treatment of rosacea
por: Jackson, J Mark, et al.
Publicado: (2015)

Review of miglustat for clinical management in Gaucher disease type 1
por: Ficicioglu, Can
Publicado: (2008)

Bone turnover markers in patients with type 1 Gaucher disease
por: Giuffrida, Gaetano, et al.
Publicado: (2012)

Gaucher's disease
por: Bohra, Vijay, et al.
Publicado: (2011)

Drug–Drug Interactions Of Amiodarone And Quinidine On The Pharmacokinetics Of Eliglustat In Rats
por: Wang, Qiong, et al.
Publicado: (2019)

Gaucher Disease and Gaucher Cells
por: Gözdaşoğlu, Sevgi
Publicado: (2015)

Neurocognitive profile of adults with the Norrbottnian type of Gaucher disease
por: Tsitsi, Panagiota, et al.
Publicado: (2021)

The Treatment of Rhinosporidium by Antimony Tartrate
por: Wright, Robert E.
Publicado: (1923)

Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1
por: Dardis, A., et al.
Publicado: (2022)

Are There Neurological Symptoms in Type 1 of Gaucher Disease?
por: ALAEI, Mohammadreza, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_upm0a0tnb468lks7ahk6tmjqle